Human immunodeficiency virus prevention and the potential of drug abuse treatment
| Autor: | Helen Navaline, David S. Metzger |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Microbiology (medical)
Drug medicine.medical_specialty Substance-Related Disorders media_common.quotation_subject medicine.medical_treatment HIV Infections Heroin Cocaine-Related Disorders Risk-Taking Acquired immunodeficiency syndrome (AIDS) medicine Humans Psychiatry Health Education media_common business.industry Addiction Public health Drug detoxification HIV medicine.disease United States Substance abuse Infectious Diseases Drug and Narcotic Control Public Health business medicine.drug Methadone |
| Zdroj: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 37 |
| ISSN: | 1537-6591 |
| Popis: | Since first recognition of the scope of the acquired immunodeficiency syndrome epidemic among the drug-using community, substance abuse treatment has been viewed as playing an important role in preventing new infections. In the past 20 years, many studies have documented significantly lower rates of drug use, drug-related risk behaviors, and human immunodeficiency virus (HIV) infections among drug users who remain in treatment programs. There is also growing evidence that drug detoxification alone is insufficient to provide protection from HIV infection. These findings have important implications for users of cocaine and noninjection drugs, as well as heroin injectors. Despite strong evidence of effectiveness and widespread support for the important public health role of drug treatment, its impact has been compromised by limited availability and acceptability. The available data clearly establish drug abuse treatment as HIV prevention, yet without expansion of existing treatment programs and the continued development of treatments for addiction to cocaine and other widely used stimulants, its public health potential cannot be realized. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|